Impact of red blood cell transfusion dose density on progression-free survival in patients with lower-risk myelodysplastic syndromes

Progression-free survival (PFS) of patients with lower-risk myelodysplastic syndromes (MDS) treated with red blood cell transfusions is usually reduced, but it is unclear whether transfusion dose density is an independent prognostic factor. The European MDS Registry collects prospective data at 6-mo...

全面介紹

Na minha lista:
書目詳細資料
發表在:Haematologica
Main Authors: de Swart, Louise, Crouch, Simon, Hoeks, Marlijn, Smith, Alex, Langemeijer, Saskia, Fenaux, Pierre, Symeonidis, Argiris, Cermâk, Jaroslav, Hellström-Lindberg, Eva, Stauder, Reinhard, Sanz, Guillermo, Mittelman, Moshe, Holm, Mette Skov, Malcovati, Luca, Mądry, Krzysztof, Germing, Ulrich, Tatic, Aurelia, Savic, Aleksandar, Almeida, Antonio Medina, Gredelj-Simec, Njetocka, Guerci-Bresler, Agnes, Beyne-Rauzy, Odile, Culligan, Dominic, Kotsianidis, Ioannis, Itzykson, Raphael, van Marrewijk, Corine, Blijlevens, Nicole, Bowen, David, de Witte, Theo
格式: Artigo
語言:Inglês
出版: Ferrata Storti Foundation 2020
主題:
Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC7049377/
https://ncbi.nlm.nih.gov/pubmed/31171638
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2018.212217
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍